Press release -
CTC and Immuneed present a seminar: "Manage risk and build value in early clinical development"
Registration is officially open for the seminar: "Manage risk and build value in early clinical development – A unique approach to integrate preclinical and clinical research". First out is Lund, 12th March.
In a close partnership, Immuneed and CTC Clinical Trial Consultants AB offer a total solution for the preclinical and clinical characterisation of a drug. By using a unique approach, we help manage risk and build value in early clinical development. Join our seminar "Manage risk and build value in early clinical development" and learn more about the preclinical human model.
During this spring, CTC and Immuneed will visit Lund, Umeå and Gothenburg. First out is Lund on the 12th of March.
Moderator is Bengt Dahlström, Ph.D., Assoc. Professor, CSO and Chairman of the Board at CTC Clinical Trial Consultants AB.
Agenda
08:15 Registration opens
08:30 From pre-clinical progress to clinical failure: is there a need for new models?
A poor success rate in clinical trials undermines the validity of the traditional pre-clinical models. Improving the current models and implementing more relevant human based assays is needed for pre-clinical data to become more clinically significant.
Justyna Leja Jarblad, COO, Immuneed AB
09:30 First-in-Human studies, where safety comes first
Solid and relevant pre-clinical data enable a profound risk mitigation strategy to minimise the risk of first-infusion reactions in your FIH study where the safety and wellbeing of the participating subjects are top priority.
Anders Millerhovf, CEO, CTC Clinical Trial Consultants AB
10: 00 The whole blood loop system, a new tool for advanced ex-vivo characterization
Pre-clinical characterization of biotherapeutics in physiologically relevant models prior to clinical studies is a key for better understanding of the function and safety risks of candidate drugs and to increase the likelihood of future clinical success.
Erika Fletcher, Head of Research, Immuneed AB
10:30 Coffee break
10:45 Early Proof-of-Concept, build value in your clinical trial
The combined expertise offered by CTC and Immuneed will support you in the design and conduct of your clinical trials. Early effect data may contribute to a significant increase in product value prior to Phase II.
Fredrik Hansson, Director Biometrics, CTC Clinical Trial Consultants AB
11:15 Summary and closing
Bengt Dahlström, CSO/Chairman of the Board, CTC Clinical Trial Consultants AB
11:30 Lunch
For registration, contact us by email: registration@ctc-immuneed.com
No later than 5th March, 2019
Topics
- Medical research
Categories
- preclinical human model
CTC Clinical Trial Consultants AB is a full-service CRO with focus on clinical conduct. Our mission is to facilitate clinical and translational research by providing our customers with cost-effective advice, conduct and reporting of clinical trials. We have four different departments: Clinic, Clinical Operations, Pharmacovigilance and Biometrics, all supported by independent quality assurance management.
Our head office and Phase 1 units are located in Uppsala comprising 28 beds of which 12 are hospital beds in a first-in-human approved research unit whereas our two professional sites for multicenter studies (SMOs) are found in Uppsala and Linköping. We have our own subject database for recruitment of both healthy volunteers and special patient populations.
CTC was founded in 2011 and has successfully conducted over 200 industry sponsored clinical trials for start-up companies as well as for international pharmaceutical companies and CROs. Our track record includes first-in-human, food effect, drug interaction, bioequivalence, bioavaliability and biosimilar studies, new drug delivery systems, medical device, PET/MR, QT and Phase IIa studies.
